MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$214,000K
Net Income
-$92,000K
Net Profit Margin
-42.99%
EPS
-$0.9
Unit: Thousand (K) dollars
Revenue Breakdown
Crysvita-Royalty
Crysvita
Dojolvi
Others
Revenue Breakdown
North America
Latin America
EMEA
Asia Pacific
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
214,000
136,000
207,279
159,933
Cost of sales
34,000
30,000
29,345
27,991
Research and development
167,000
187,000
203,280
216,212
Selling, general and administrative
88,000
88,000
87,937
86,620
Total operating expenses
289,000
305,000
320,562
330,823
Loss from operations
-75,000
-169,000
-113,283
-170,890
Interest income
5,000
6,000
6,512
5,863
Change in fair value of equity investments
-
-
-
678
Non-cash interest expense on liabilities for sales of future royalties
22,000
21,000
19,469
14,148
Other income
1,000
-
-934
-1,043
Loss before income taxes
-91,000
-184,000
-127,686
-179,540
Provision for income taxes
1,000
1,000
870
873
Net loss
-92,000
-185,000
-128,556
-180,413
Basic EPS
-0.9
-1.84
-1.287
-1.81
Diluted EPS
-0.9
-1.84
-1.287
-1.81
Basic Average Shares
101,900,000
100,600,000
99,879,608
99,771,297
Diluted Average Shares
101,900,000
100,600,000
99,879,608
99,771,297
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
-$92,000K
(19.97%↑ Y/Y)
Crysvita
$54,000K
(55.50%↑ Y/Y)
Dojolvi
$27,000K
(16.34%↑ Y/Y)
Evkeeza
$21,000K
(44.10%↑ Y/Y)
Mepsevii
$10,000K
(20.34%↑ Y/Y)
Loss before income
taxes
-$91,000K
(20.18%↑ Y/Y)
Provision for income taxes
$1,000K
(5.60%↑ Y/Y)
Interest income
$5,000K
(-13.70%↓ Y/Y)
Other income
$1,000K
(-53.27%↓ Y/Y)
Product
$112,000K
(38.58%↑ Y/Y)
Crysvita-Royalty
$102,000K
(19.05%↑ Y/Y)
Loss from operations
-$75,000K
(30.48%↑ Y/Y)
Non-cash interest
expense on liabilities...
$22,000K
(56.68%↑ Y/Y)
Total revenues
$214,000K
(28.53%↑ Y/Y)
Total operating
expenses
$289,000K
(5.33%↑ Y/Y)
Research and development
$167,000K
(1.37%↑ Y/Y)
Selling, general and
administrative
$88,000K
(1.56%↑ Y/Y)
Cost of sales
$34,000K
(47.81%↑ Y/Y)
Buy us a coffee
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)